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INTRODUCTION
Recurrent respiratory papillomatosis
(RRP) is a disease of the upper airway
characterized by persistent human papil-
lomavirus type 6/11 (HPV 6/11) infec-
tion that results in the chronic recurrence
of benign tumors that can cause com-
plete laryngeal occlusion. HPV infection
of the airway is not uncommon, yet RRP
is a rare disease. We have reported previ-
ously that patients with RRP have a bi-
ased TH2-like and/or Treg, antiinflamma-
tory adaptive immune response to these
HPVs (1–3). To determine the repertoire
of immunologically relevant genes and
pathways that are responsible for this
skewed adaptive response, we previ-
ously performed a paired microarray
analysis using papilloma tissues and
clinically normal laryngeal tissues from
the same patient to identify differential
expression of genes and gene pathways
in the papillomas (4). We observed that
expression of the proinflammatory cy-
tokine IL-36γ was markedly upregulated.
In marked contrast to this observation,
papilloma tissues fail to show signs of in-
flammation. To explore this paradox, and
better understand why the immune sys-
tem of RRP patients fails to control per-
sistent laryngeal HPV infection, we have
now addressed the innate immune re-
sponses made by Langerhans cells (LCs)
in response to IL-36γ in patients with
RRP.
IL-36γ is a member of the IL-1 super-
family that includes three closely related
genes, IL-36α, β, and γ, formerly known
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as IL-1F6, F8, and F9 respectively. IL-
36α has been detected in both neuronal
and synovial tissue, whereas IL-36β and
IL-36γ are expressed in both cutaneous
and mucosal epithelial cells, including
the respiratory tract. IL-36β and IL-36γ
stimulate proliferation, maturation
and/or cytokine expression by innate
immune cells (such as keratinocytes and
dendritic cells), and adaptive immune
cells (neutrophils and T-cells) in both
humans (5–8) and mice (9). A genetic
defect in the regulation of IL-36γ stimu-
lation results in the multisystemic in-
flammatory disease termed generalized
pustular psoriasis (10), illustrating the
importance of proper regulation of the
proinflammatory signaling pathway
mediated by IL-36 ligands in maintain-
ing a normal epithelium (11).
The specific effect of IL-36γ stimula-
tion of LCs, which are the resident pro-
fessional antigen-presenting cells
within the epithelium of the skin and
mucosa, has not been described previ-
ously. Here we provide the first evi-
dence that immature, monocyte-derived
Langerhans cells (iLCs) respond to IL-
36γ stimulation by increasing the ex-
pression of a specific subset of proin-
flammatory cytokines and chemokines.
Monocyte-derived iLCs from patients
with RRP show impaired upregulation
of inflammatory mediators, especially
CCL-20, following stimulation by IL-
36γ, coupled with a lower basal expres-
sion of CCL-1 that correlates with dis-
ease severity. In addition, IL-36γ
stimulation of both laryngeal and fore-
skin keratinocytes increases the expres-
sion of IL-36γ mRNA itself, similar to
that observed for both IL-36β and IL-1β
(12,13) indicating that a positive au-
tocrine feedback loop exists in ker-
atinocytes. However, we also find that
HPVs can interfere with IL-36γ protein
release from infected keratinocytes,
which would further reduce the re-
sponse by resident iLCs in papilloma
tissues. Taken together, these results
suggest that the normal innate immune
function of LCs in response to IL-36γ is
impaired in RRP.
MATERIALS AND METHODS
Sample Collection and Preparation
Respiratory papilloma tissue and clini-
cally normal adjacent laryngeal biopsies
were obtained during surgery to remove
papillomas. Neonatal foreskin tissues were
obtained following circumcision. Tissues
were either snap frozen or cultured to gen-
erate primary cells as described previously
(14). Airway keratinocytes were used at
passage two or three. Foreskin keratino -
cytes were incubated in dispase at 4°C
overnight, trypsinized and plated as
single cells in keratinocyte culture media
(3:1 DMEM:Ham’s F-12, 10% FetalClone
II [Fisher Scientific, Pittsburgh, PA, USA
{Thermo Fisher Scientific Inc., Waltham,
MA, USA}], 0.4 μg/mL hydrocortisone,
0.1 nmol/L cholera toxin, 5 μg/mL trans-
ferrin, 2 nmol/L 3,3′-5- triiodo-L-thyronine,
5 ng/mL epidermal growth factor [EGF],
5 μg/mL insulin, 10 units/mL penicillin
and streptomycin) in the presence of
 mitomycin C-treated J2-3T3 feeder layers,
and used no later than passage five.
Whole blood from patients was collected
in heparin-coated tubes at the time of
surgery. The disease severity score for
each patient studied is a composite value
of the rate of regrowth of papilloma mass
divided by the time in days since the pre-
vious surgery (15,16). Any score over 0.06
is classified as severe disease. Control
blood was collected from volunteers with
no history of RRP. All patients and con-
trols signed consent forms, and all stud-
ies were approved by the Institutional
Review Board, Feinstein Institute for
Medical Research, North Shore-LIJ
Health System, Great Neck, NY, USA.
Western Blot
Pulverized frozen tissues and cultured
cells were extracted in Tris/NP-40/ EDTA
(TNE) buffer (0.1 mol/L Tris pH 8.0, 1%
NP-40, 5 mmol/L EDTA) supplemented
with a protease inhibitor cocktail (Roche
Diagnostics, Indianapolis, IN, USA) for
30 min with final protein concentrations
determined as described previously (17).
Proteins (20 μg per lane) were separated
on 8%-16% SDS-PAGE gels, (Bio-Rad,
Hercules, CA, USA) electro blotted onto
Immobilon-FL membranes, (Millipore,
Billerica, MA, USA) and imaged with the
LI-COR Odyssey (LI-COR Biotechnology,
Lincoln, NE, USA).
Lentiviral Transduction and Analysis of
IL-36γ Release
The upstream regulatory region (URR)
and early genes of HPV (nt7178-5963)
were ligated into the lentiviral vector
pSMPUW (Cell Biolabs, San Diego, CA,
USA) to create a lentiviral vector in which
all early genes of HPV11 are expressed
under the control of their endogenous
HPV promoters. Early passage human
foreskin keratinocyte cultures (HFKs) de-
rived from multiple specimens and
pooled, were infected with 90 copies per
cell of the HPV11-lentiviral vector, or with
the empty vector as a control, and cul-
tured for one week. Total RNA was iso-
lated from transduced HFKs with the
Roche High Pure RNA Isolation Kit
(Roche Diagnostics); Q-PCR was per-
formed using primers specific for
HPV11E7 (forward primer nt133–nt157,
reverse primer nt195–nt212, probe
nt161–nt184); and the signal was com-
pared with that for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) to
confirm transduction and viral expres-
sion. Transduced keratinocytes containing
either HPV11 or empty vector (control),
were treated with poly (I:C) (HMW) (In-
vivoGen, San Diego, CA, USA) for 96 h,
after which supernatants were analyzed
by IL-36γ enzyme-linked immunosorbent
assay (ELISA) (Human IL-1F9 ELISA kit,
 Aviscera Bioscience, Santa Clara, CA,
USA). The percentage of cell death was
determined by trypan-blue staining of
treated cells, and by measurement of lac-
tic dehydrogenase in the supernatant as
per the manufacturer (Cytotoxicity Detec-
tion Kit (LDH), Roche Diagnostics).
Isolation, Culture, and Flow Cytometry
Characterization of Monocyte-
Derived Langerhans Cells
Mononuclear cells were isolated from
peripheral blood using Ficoll-Paque den-
sity gradient centrifugation (GE Health-
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care, Fairfield, CT, USA). Monocytes
were negatively selected using a com-
mercially available magnetic isolation kit
(Monocyte Isolation Kit II, Miltenyi
Biotec, Bergisch Gladbach, Germany),
which consistently yielded greater than
90% purity. Isolated monocytes were
suspended at 1 × 106/mL in RPMI 1640
media (Gibco/Life Technologies
[Thermo Fisher Scientific Inc.]) contain-
ing 10% fetal bovine serum (FBS) (At-
lanta Biologicals, Flowery Branch, GA,
USA), 100 ng/mL granulocyte-
macrophage colony- stimulating factor
(GMCSF), 20 ng/mL IL-4 and 10 ng/mL
TGFβ1 (R&D Systems, Minneapolis,
MN, USA) (18,19). Monocyte cell sus-
pensions were cultured in 6-well poly-
styrene trays (Falcon, Fisher Scientific
[Thermo Fisher Scientific Inc.]) and sup-
plemented with fresh medium without
IL-4 on d 1 and d 4. On d 6 or 7, cells
were harvested, stained for viability
(Live/ Dead Fixable Aqua Dead Cell
Stain Kit [Invitrogen/Life Technologies
{Thermo Fisher Scientific Inc.}]) and then
surface stained with fluorochrome-
 labeled antibodies CD324 APC (BioLe-
gend, San Diego, CA, USA), CD207 PE
and CD1a PE (Beckman Coulter, Brea,
CA, USA), CD83 APC and CD14 Pacific
Blue, (BD Biosciences, San Jose, CA,
USA). After washings, cells were resus-
pended in 1% formaldehyde and ana-
lyzed on a FACSCanto II. Forward scat-
ter area versus forward scatter height
gating was used to remove cell aggre-
gates. Viable cells with large forward
and side scatter properties were ana-
lyzed using FlowJo version 7.2.5
(TreeStar, Ashland, OR, USA). Positive
fluorescence staining was established
using isotype and fluorescence minus
one control.
IL-36γ Stimulation and Analysis of
Monocyte-Derived Immature
Langerhans Cells
The iLCs (2.5 × 106; d 6 or 7) were re-
suspended in media without cytokines
and stimulated for 4 h at 37°C with
10 ng/mL of recombinant active IL-36γ
(aa 18-169) (R&D Systems), or with the
recombinant inactive full length IL-36γ
(aa 1-169) as a control. Cells were col-
lected by centrifugation, and total RNA
isolated, following DNase1 treatment,
as per manufacturers instructions (Qia-
gen, Valencia, CA, USA). RNA integrity
(RIN > 7.0) was measured using a Bio-
analyzer (Agilent Technologies, Santa
Clara, CA, USA). For microarray analy-
sis, total RNA (300 ng) was reverse
transcribed and biotin-labeled prior to
hybridization to Human HT-12V4 ex-
pression arrays (Illumina, San Diego,
CA, USA) as described previously (4).
Data were processed using BeadStudio
(Illumina), and tab-delimited text files
were uploaded to GeneSifter software
(Geospiza Inc., Seattle, WA, USA) and
comparisons of various experimental
conditions analyzed.
For quantitative reverse transcription
polymerase chain reaction (RT-PCR)
analysis, gene-specific intron-spanning
primers were purchased from Applied
Biosystems/Life Technologies (Thermo
Fisher Scientific Inc.), or designed using
a free bioinformatics program (Table 1)
available on the Fisher website (Fisher
Scientific, [Thermo Fisher Scientific Inc.])
and RT-Q-PCR performed on an Ap-
plied Biosystems 7900 HT (Applied
Biosystems/ Life Technologies) using the
appropriate universal probes (Roche) to-
gether with the insert iScript One-Step
RT-PCR kit (Bio-Rad). Ten nanograms of
total RNA was reverse transcribed at
50°C for 10 min, followed by a 5 min hot
start at 95°C followed by 40 cycles of 
2-step PCR at 95°C for 15 sec and 60°C
for 1 min. Individual RNA samples were
run in duplicate and the average Ct val-
ues for the gene of interest compared
with the average Ct values for a house-
keeping gene (GAPDH) to calculate
δδCt, where fold change = 2[δδCt].
RESULTS
IL-36γ Protein is Expressed in
Respiratory Papillomas
We demonstrated previously that
IL-36γ mRNA is elevated in respiratory
papillomas and that expression corre-
lated with disease severity (4). We now
have confirmed that IL-36γ protein also
was elevated in papilloma tissues in
comparison to clinically normal (CN)
autologous laryngeal epithelium (Fig-
ure 1). Shown are Western blots of two
representative pairs of matched tissue
sets. All papilloma tissues examined 
(n = 6) expressed abundant IL-36γ pro-
tein, which was not detectable at any
appreciable levels in any of the matched
CN tissues.
HPV-11 Suppresses IL-36γ Release
from Keratinocytes
Since respiratory papillomas express
increased IL-36γ mRNA and protein, we
Table 1. RT-Q-PCR primers and probes.
Forward primer Reverse primer Probe Gene name
TACCTGTCCTGCGTGTTGAA TCTAGGGTTTTTAATGGGTTTCT AGCTGGAG IL-1β NM_000576.2
AAGTTTTACATGCCCAAGAAGG AAGTGAAAGTTTTTGCTTTGAGCTA CTGGAGGA IL-2 ENST00000226730.3
TGTTCATTTATGGAAGGGATGA TTCTGCTTTTCTTTACGTTTTCATT TGGGGAAG IL-1R1
CCCTGTGATCCATTCACCTAA TGCGAGAATCCATCAGAAAAC TCCTCTCC IL-1RacP
GCTGGAGTGTCCACAGCATA GCGATAAGCCCTCCTATCAA CAGCTCCC IL-1R6
TGAGAGGCACTCCAGGAGAC AGGGTCCACACTTGCTGATT TGGTGGAG IL-36γ
GATGAGTACAAAAGTCCTGATCC CTGCAGCCACTGGTTCTGT CAGCAGGC IL-6
TTGCTGCTAGCTGGGATGT CTGGAGAAGGGTACCTGCAT TGCTGTCC CCL-1
GTGGCTTTTCTGGAATGGAA CAACCCCAGCAAGGTTCTT UPL-H117 CCL-20
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then asked whether HPV infection pre-
vents the release of this proinflamma-
tory cytokine. Others have shown that
high concentrations (2.5–25 μg/mL) of
the synthetic TLR-3 ligand poly (I:C),
which is an analog of double-stranded
RNA, can induce release of IL-36γ from
human foreskin keratinocytes (HFKs)
by inducing cell death (20). We have
found that HFKs can be induced to se-
crete IL-36γ protein at much lower con-
centrations of poly (I:C) (0.25–0.75
μg/mL) without any detectable cell
death. The amount of IL-36γ secreted in
response to low dose poly (I:C) was
markedly decreased in cells transduced
by HPV-11, but was not completely
blocked (Figure 2A). This difference in
secretion was not caused by differences
in protein expression, since intracellular




Since papillomas contain IL-36γ pro-
tein, and at least some IL-36γ can be re-
leased from keratinocytes infected with
HPV-11, we asked whether the lack of
inflammation in papillomas reflected
the absence of LCs in the epithelium.
We used immunohistochemistry to de-
termine whether LCs were present in
papillomas and found that they were
easily identified and abundant in papil-
loma tissues (Figure 3A). These cells
had the morphology of dendritic cells
when visualized at high magnification
(Figure 3B). They expressed both CD1a
(Figure 3C) and langerin (CD207) (Fig-
ure 3D) but not the maturation marker
CD83 (Figure 3E). Thus, the numerous
LCs in papillomas are immature (iLCs).
We were able to isolate iLCs from small
papilloma biopsies (Figure 3G), and we
determined that they were approxi-
mately half as frequent as the lympho-
cytes that we have previously charac-
terized in respiratory papillomas
(21,22). The absence of both CD14 and
CD1a expression (Figure 3H) confirmed
that they were indeed resident iLCs,
Figure 1. IL-36γ protein is overexpressed in
papilloma tissues. Western blot showing IL-
36γ expression levels in papilloma tissue (P)
and autologous clinically normal laryngeal
tissue (CN) from RRP patients. β-actin (lower
panel) shown as a loading control. Repre-
sentative of six matched pairs of tissues.
Figure 2. HPV-11 suppresses release of IL-36γ from keratinocytes. Human foreskin keratinocytes
that had been transduced with either a lentivirus construct expressing all early HPV-11 genes
or the empty vector were treated with poly(I:C) or solvent for 96 h. IL-36γ release was mea-
sured by ELISA (A), with results shown as the mean ± SD of three assays, *p < 0.05. Compara-
ble levels of intracellular IL-36γ were confirmed by Western blot (B).
Figure 3. Papillomas contain abundant iLCs. iLCs were CD1a+ (A,B) and langerin+ (C,D),
but CD83– (E). A positive control (lymphoma) was CD83+ (F). (A–B) Paraffin sections, DAB
stain. (C–D) frozen sections, AEC stain. (E–F) Paraffin sections, immunofluorescence with
DAPI counterstain. (G, H) Flow cytometry of LCs isolated from papilloma biopsies. LCs (G,
lower right) were approximately half as frequent as T-cells (G, upper left). LCs were CD14
negative (H, lower right), confirming that they were not monocytes and that there was no
significant contamination by blood.
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and not simply monocytes from the
blood vessels that permeate respiratory
papillomas.
IL-36γ Induces iLCs to Express
Proinflammatory Cytokines and
Chemokines, but iLCs from Patients
with RRP Show Reduced Responses
Compared with Controls
Because iLCs were present in papillo-
mas, we questioned whether they were
able to respond to IL-36γ. However, noth-
ing was known about the response of
normal iLCs to this cytokine. We there-
fore first characterized the response of
control iLCs to recombinant IL-36γ, using
monocyte-derived iLCs because they are
abundant and the number of resident
iLCs that can be derived from tissue
biopsies is limited. These blood-derived
iLCs expressed CD1a and E-cadherin on
their cell surfaces, and approximately
half of the cells also expressed langerin
(Figure 4A). The CD1a+ cells were CD83
negative (Figure 4B), consistent with our
finding in papillomas (see Figure 3E) and
reports that characterized resident LCs in
the airway mucosa as immature (23).
Furthermore, they were functional, since
they could be induced to mature when
stimulated with either IL-36γ or
lipopolysaccharide (LPS) (Figures 4C–E).
We initially performed dose response
and time course experiments to deter-
mine the optimal conditions for IL-36γ
stimulation. Monocytes on d 2, prior to
differentiation into iLCs, did not re-
spond to IL-36γ but responded to IL-1β
and to lipopolysaccharide (LPS) as ex-
pected (data not shown). At d 6, after
differentiation into iLCs, the cells re-
sponded to IL-36γ with statistically sig-
nificant increases in mRNA expression
of both inflammatory cytokines and
chemokines (Figure 5). The response
was detectable at 2–5 ng/mL and maxi-
mal at 10–20 ng/mL for all individuals
tested. Comparison of 4, 6 and 8 h expo-
sure to IL-36γ revealed that maximal re-
sponses were observed at 4 h and de-
creased thereafter.
IL-36γ signals through a single het-
erodimer receptor comprised of IL-1R6
and the receptor accessory protein IL-
1RacP (IL-1R3). This receptor accessory
protein is common to both the IL-36 re-
ceptor and the IL-1 receptor (IL-1R1)
(24). We therefore asked if the expression
of the unique receptor subunit for the
IL-36 receptor changed from d 2 to d 6 of
culture. While IL-1R6 mRNA levels were
four- to eight-fold lower than IL-1R1 and
IL-1RacP, they were still expressed at rel-
atively high levels in the d 2 cells and the
mRNA levels for each of the unique re-
ceptor subunits (IL-1R1, IL-1R6), as well
as the common accessory protein IL-
1RacP, were unchanged between d 2 and
d 6 (Figure 6). This result suggested that
the change in ability to respond to IL-36γ
is not determined by increased expres-
sion of either subunit.
Six cultures of iLCs (three from pa-
tients with RRP and three controls) were
studied by gene microarray to identify
the broad repertoire of genes that were
upregulated by IL-36γ stimulation.
Among the top 20 genes upregulated at
least three-fold above baseline (Table 2),
seven encoded either cytokines or
Figure 4. Characterization of LCs generated from peripheral blood monocytes. iLCs were generated from isolated peripheral blood
monocytes by incubating blood monocytes with GMCSF, TGF-β1, and IL-4. After 6 d, they were analyzed by flow cytometry. The cells were
E-cadherin+ and approximately 50% were langerin+ (A), but immature (CD83–) (B). Day 11 iLCs (C) could be induced to mature, as mea-
sured by surface expression of CD83 and HLADR, when stimulated with either IL-36γ (D) or LPS (E) for 48 h.
Figure 5. Response of iLCs to IL-36γ. Cells were stimulated with either recombinant inac-
tive, full-length (aa 1-169) IL-36γ (control) or the active, shorter form (aa 18-169) of IL-36γ
for 4 h. Induction of mRNA for specific proinflammatory cytokines (A) and chemokines (B)
was measured by q-PCR. Results are the mean ± SD of at least six separate cultures, nor-
malized to control cultures treated with solvent.
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chemokines. These genes are shown in
descending order of abundance: CCL-1,
IL-1β, LTα, CCL-20, LTβ, CXCL-1, and
TNF-α. There was no qualitative differ-
ence in the transcriptional profiles of iLCs
induced by IL-36γ stimulation between
the patients with RRP and the controls.
We then used qPCR to quantify the en-
hanced expression of select cytokines
and chemokines using a larger cohort
from controls and patients. As seen in
Figure 7, induction of several proinflam-
matory mediators was different between
the two groups. iLCs from controls
clearly responded to IL-36γ by markedly
upregulating the expression of the proin-
flammatory mediators CCL-20, and IL-1β
and TNF-α (see Figure 7), and IL-6 which
can be either pro- or antiinflammatory
(25–28). The response levels varied some-
what between individuals, but they were
increased in all samples. The responses
to IL-36γ were very specific, given that
not all cytokines/chemokines were in-
duced. Expression of IL-2, IL-4, IL-8, 
IL-10, IL-12a, and IL-23 were all un-
changed (data not shown), as predicted
by the microarray analysis.
The quantitative responses by iLCs
from patients with RRP were reduced
compared with iLCs from controls, with
reduced expression of IL-1β, IL-6, TNF-α
Figure 6. Differentiation of LCs from mono-
cytes does not alter IL-1 receptor and IL-36
receptor expression. Blood-derived mono-
cytes (d 2) and iLCs derived from monoc-
tyes (d 6) were assayed for mRNA expres-
sion of IL-1R1, IL-1R3, and IL-1R6 and
compared with GAPDH mRNA expression
(δCT).
Figure 7. iLCs from patients are less respon-
sive to IL-36γ. Cells from both healthy con-
trols and RRP patients were stimulated
with active IL-36γ for 4 h, and increased
expression of proinflammatory cytokines
and chemokines measured by q-PCR. A
consistent pattern of blunted expression
by the patient- derived LCs was evident,
with the difference in CCL20 significant
and the difference in IL-1β just missing sig-
nificance. Results are the mean ± SD of at
least six separate iLC cultures from controls
and seven isolates from patients. *p < 0.05. 
Table 2. Top 20 genes upregulated by IL36γ in iLCs.
Rank 
order p Value Identifier Gene name/protein name
1 0.00258 NM_002981 Chemokine (C-C motif) ligand 1/CCL1
2 7.85e-07 XM_938742 PREDICTED: sphingosine-1-phosphate phosphotase 2 
(SGPP2), mRNA.
3 0.00065 NM_000930 Plasminogen activator, tissue
4 2.15e-06 NM_007115 Tumor necrosis factor, α-induced protein 6
5 1.36e-05 NM_000576 Interleukin 1, beta/ IL-1β
6 3.19e-07 NM_003327 Tumor necrosis factor receptor superfamily, member 4
7 5.76e-06 NM_153259 Mucolipin 2
8 1.54e-05 NM_001024465 Superoxide dismutase 2, mitochondrial
9 0.00166 NM_000595 Lymphotoxin α (TNF superfamily, member 1)
10 0.00012 NM_014398 Lysosomal-associated membrane protein 3
11 0.00031 NM_004591 Chemokine (C-C motif) ligand 20/CCL20
12 2.34e-05 NM_001024466 Superoxide dismutase 2, mitochondrial
13 3.39e-05 NM_003037 Signaling lymphocytic activation molecule family 
member 1
14 0.00035 NM_002341 Lymphotoxin β (TNF superfamily, member 3)
15 4.19e-05 NM_003088 Fascin homolog 1, actin-bundling protein 
(Strongylocentrotus purpuratus)
16 0.00113 NM_172374 Nucleoporin 62kDa
17 0.00027 NM_001511 Chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha)/CXCL1
18 0.00085 NM_001165 Baculoviral IAP repeat-containing 3
19 0.00026 NM_178452 Leucine rich repeat containing 50
20 0.00041 NM_000594 Tumor necrosis factor (TNF superfamily, member 2)/TNF-α
and CCL20 (see Figure 7). Of note, the
reduction in CCL-20 was significantly
different (p < 0.05), reduction of IL-1β ex-
pression approached significance (p =
0.06), and a trend to reduced expression
was clearly seen for IL-6 and TNF-α. It is
possible that analysis of a larger cohort
of patients would show a significant re-
duction in the levels for all four immune
mediators.
Constitutive CCL-1 Expression by iLCs
from Patients’ with RRP Correlates with
Disease Severity
CCL-1 was the most elevated immune
mediator following IL-36γ stimulation,
increasing more than 100-fold (p < 0.05)
in controls, but mean levels of induction
did not differ between RRP patients and
controls. However, there was consider-
able variability in the baseline levels of
CCL-1 expressed by the patients’ cells.
We therefore asked whether there was a
correlation between CCL-1 mRNA levels
in unstimulated iLCs from patients and
the severity of their disease (Figure 8).
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The highest constitutive expression was
detected in patients with mild disease, at
levels comparable to the controls without
RRP. In contrast, there was significantly
lower baseline expression in patients
with moderate or severe disease, with
the most severe patients having the low-
est baseline levels. Thus, low constitutive
CCL-1 mRNA expression by iLCs from
patients predicted disease severity.
DISCUSSION
Infection of laryngeal keratinocytes
with HPV6/11 induces the production of
a number of inflammatory cytokines, in-
cluding IL-36γ, which should facilitate a
proinflammatory adaptive immune re-
sponse that ultimately results in the
clearance or control of this infection. The
chronic nature of RRP suggests that, es-
pecially for those with severe disease, an
effective adaptive immune response to
these viruses is not achieved. We previ-
ously showed that the adaptive immune
responses made by RRP patients are po-
larized toward immune tolerance of
HPVs, with a strong TH2-like and/or
Treg bias (29–32). However, the innate re-
sponses that orchestrate the polarization
of the adaptive immune responses to
these viruses had not yet been character-
ized, and were the focus of this study.
Airway epithelial cells constitute the
primary antimicrobial defense against
aerosolized pathogens by providing a
physical barrier that is enhanced by the
production of mucus and the expression
of proinflammatory cytokines, chemoat-
tractants, and defensins which we have
previously shown to be upregulated in
RRP (4). We also reported that a single
member of the IL-1 superfamily, the
proinflammatory cytokine IL-36γ, was
markedly and consistently upregulated in
respiratory papillomas, yet there was no
evidence of inflammation in these tissues
(4). Select members of the IL-36 family of
cytokines are expressed by both mouse
and human bronchial epithelial cells
(33,34), and by laryngeal keratinocytes
(4). Unopposed signaling from the IL-36
receptor, secondary to the functional loss
of the IL-36 receptor antagonist (IL-36Ra)
has been shown to lead to the severe der-
mal inflammatory disease generalized
pustular psoriasis (10), illustrating the
strong proinflammatory effects of unreg-
ulated IL-36 signaling in the epidermis.
Although it has been shown previously
that myeloid dendritic cells can respond
to IL-36γ (35), those authors used the full
length, inactive form of the protein, which
precluded an appreciation of how this cy-
tokine triggers a proinflammatory re-
sponse (9). They also suggested that LC
might respond to IL-36γ, but did not dem-
onstrate this. LCS are a migratory subset
of dendritic cells that specialize in uptake,
transport, processing and presentation of
antigens to T-cells (36–39), and are essen-
tial in generating Tregs that induce toler-
ance in vitro and in vivo (40). LCs mature
during antigen encounter and migrate to
lymph nodes (41) where they present
peptides to T-cells. The balance of pro-
and antiinflammatory cytokines made by
keratinocytes (42–44), with contributions
from LCs themselves, influence LC migra-
tion, maturation, and function.
There is considerable plasticity in LCs
that skews T-helper cell responses, depen-
dent upon the antigen and the cytokine
milieu present during this encounter (45).
LCs can induce TH1 responses but also
can be converted to support TH2 re-
sponses when IL-10 is present (41,46–52).
Thus, LCs can function as either pro- or
antiinflammatory (53–57) mediators of
adaptive immunity. Others have reported
that IL-36β, which binds to the same re-
ceptor (IL-1R6) as IL-36γ, can increase ex-
pression of IL-12p70 and IL-18 by mono-
cyte-derived DCs, and thereby induce
IFN-γ expression by human TH1-like 
T-cells(6). They also reported that IL-36γ
can mature these DCs, manifested by in-
creasing their expression of HLA-DR and
CD83 and reducing CD1a (6). We previ-
ously showed that both IL-4 and IL-10 (1)
are expressed in papillomas with little if
any IFN-γ, IL-12, or IL-18 (58,59).
CONCLUSION
In this study, we have shown for the
first time that iLCs generated from pe-
ripheral blood monocytes respond to IL-
36γ by upregulation of additional spe-
cific proinflammatory cytokine and
chemokine mRNAs, with high levels of
IL-1β and CCL1 mRNA, and moderate
levels of TNF-α, demonstrating that they
clearly could support adaptive TH1-like
T-cell responses (see Figures 5,7). Their
expression of IL-6 and CCL20 showed
that they also could support TH2-like re-
sponses, which has recently been sug-
gested to be the principle role of LCs in
the epidermis (60,61). Acquisition of the
ability to respond to IL-36γ required dif-
ferentiation to iLCs, since monocytes did
not respond. The mechanism of this dif-
ference has not been elucidated, al-
though we have ruled out a difference in
IL-36γ receptor mRNA expression (see
Figure 6). We have been unable to mea-
sure receptor protein expression or sur-
face localization using commercially
available antibodies. Future studies will
determine whether there are differences
in activation of signal transduction path-
way intermediates downstream of the
receptor.
Figure 8. Expression of CCL1 in iLCs corre-
lates with severity of RRP. The level of con-
stitutive CCL1 expression in iLCs from pa-
tients with RRP was determined by q-PCR.
Expression levels in iLCs from eight controls
were defined as 100%; and individual sam-
ples clustered tightly around the 100%
value (not shown); there was nearly a two-
log reduction in expression as severity in-
creased in the patients, p < 0.0001. Dis-
ease severity score is a composite value
of the rate of regrowth of papilloma mass
divided by the time in days since the pre-
vious surgery. A score over 0.06 is classified
as severe disease.
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The cytokine/chemokine responses of
iLCs from patients stimulated with IL-
36γ were qualitatively similar to controls,
but the responses were generally less ro-
bust (see Figure 7). The lower baseline
expression of the proinflammatory
chemokine CCL-1 in iLCs from patients
with the most severe disease could pro-
vide significant insight into the mecha-
nism underlying our earlier studies of
the adaptive response in RRP which
showed that the more extreme the 
TH2-like/Treg cytokine polarization of
adaptive immune responses made by pa-
tients with RRP, the more severe the dis-
ease (4,29,31,32,62). CCL-1 links adaptive
and innate immune function by recruit-
ing LC-like dendritic cells and cytotoxic
CD8+ T-cells (63). CCL-1 is required
along with CCL-17 for the IL-12-induced
coupling of dendritic cells and CD8+
T-cells to generate IFN-γ (64). IL-12 ex-
pression and the presence of functional
cytotoxic T-cells are both reduced in RRP,
and IFN-γ expression is extremely low,
while CCL-17 is not reduced (1,31), sug-
gesting that deficient IL-12, linked with
disproportional CCL-1/CCL17 expres-
sion, would reduced dendritic cell-naïve
CD8+ T-cell priming leading to reduced
IFN-γ production which is characteristic
of adaptive response in RRP (1,32).
We were surprised by the reduced ex-
pression of CCL20 by patients’ iLCs in re-
sponse to IL-36γ, since this chemokine is
important in recruiting Tregs and LCs
into tissues (23,65,66) and both are abun-
dant in papillomas (22). However, newly
recruited LCs are required for CD8+ T-cell
priming to microbial proteins and adju-
vants such as poly(I:C) and flagellin, and
for their subsequent expression of IFN-
γ(23). Thus, reduced expression of CCL20
by iLCs from RRP patients would alter
the balance between resident and newly
recruited LCs. This, in conjunction with
low baseline levels of CCL-1, may explain
the failure of CD8+CD28– T-cells that are
enriched in respiratory papillomas (29) to
support an inflammatory response.
In summary, we demonstrate, for the
first time, that iLCs respond to IL-36 ago-
nists by increasing their expression of
both pro- and antiinflammatory inter-
leukins and chemokines, but that patients
with RRP have a lower level of response.
Our findings also suggest that sup-
pressed IL-36γ release by HPV-infected
keratinocytes, coupled with the systemic
alterations in iLCs, results in suppressed
innate signaling that contribute to the in-
effective adaptive immune responses to
HPV by patients with RRP. Further char-
acterization of the response of resident
iLC in respiratory papillomas to IL-36γ
and other cytokines, together with illumi-
nating the mechanism(s) by which HPVs
alter IL-36γ release, should provide criti-
cal insight into how these viruses evade
the normal mucosal immune responses
and why patients with RRP are unable to
control their disease.
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